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Abstract The well-documented link between a-synuclein
and the pathology of common human neurodegenerative
diseases has increased attention to the synuclein protein
family. The involvement of a-synuclein in lipid metabolism
in both normal and diseased nervous system has been shown
by many research groups. However, the possible involve-
ment of c-synuclein, a closely-related member of the syn-
uclein family, in these processes has hardly been addressed.
In this study, the effect of c-synuclein deﬁciency on the lipid
composition and fatty acid patterns of individual lipids from
two brain regions has been studied using a mouse model.
The level of phosphatidylserine (PtdSer) was increased in
the midbrain whereas no changes in the relative proportions
of membrane polar lipids were observed in the cortex of
c-synuclein-deﬁcient compared to wild-type (WT) mice. In
addition, higher levels of docosahexaenoic acid were found
in PtdSer and phosphatidylethanolamine (PtdEtn) from the
cerebral cortex of c-synuclein null mutant mice. These
ﬁndingsshowthatc-synucleindeﬁciencyleadstoalterations
in the lipid proﬁle in brain tissues and suggest that this
protein, like a-synuclein, might affect neuronal function via
modulation of lipid metabolism.
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Abbreviations
ARA Arachidonic acid
AD Alzheimer’s disease
alphaKO a-Synuclein null mutant
Ptd2Gro Cardiolipin (diphosphatidylglycerol)
CNS Central nervous system
DHA Docosahexaenoic acid
DLB Dementia with Lewy bodies
DMA Dimethylacetal
ESI–MS-MS Electrospray ionisation tandem mass
spectrometry
FAME Fatty acid methyl ester(s)
gammaKO c-Synuclein null mutant
LIT Linear ion trap
LnA a-Linolenic acid
PD Parkinson’s disease
PtdCho Phosphatidylcholine
PtdEtn Phosphatidylethanolamine
PtdGro Phosphatidylglycerol
PtdIns Phosphatidylinositol
PNS Peripheral nervous system
PtdSer Phosphatidylserine
PUFA Polyunsaturated fatty acid(s)
CerPCho Sphingomyelin
TAG Triacylglycerol(s)
WT Wild-type
Introduction
The synuclein family comprises three small, closely-
related, natively unfolded proteins, a-, b- and c-synuclein,
that are expressed predominantly in neural tissues. Alpha-
and b-synucleins are abundant in the neurons of the central
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terminals where they are loosely associated with synaptic
vesicles. c-Synuclein is mainly cytosolic and expressed in
the neurons of the peripheral nervous system (PNS) and
certain populations of CNS neurons. c-Synuclein is also
expressed in some malignant tumours and may be involved
in tumorigenesis and metastasis [1].
Aggregated and ﬁbrillated forms of a-synuclein are
major components of Lewy bodies, histological hallmarks
of hereditary and idiopathic forms of Parkinson’s disease
(PD). Moreover, several mutations in SNCA, a gene
encoding a-synuclein, are associated with early onset
autosomal dominant PD [2–7] and polymorphisms of this
gene are risk factors for PD and other diseases associated
with a-synuclein aggregation [8–12]. The accumulation of
aggregation intermediates, i.e. partially or fully soluble
oligomeric forms of a-synuclein, is believed to be the
principle pathogenic event responsible for neuronal dys-
function [13–16] and interactions with lipids play an
important role in oligomerisation of a-synuclein [17–19].
Interestingly, b- and c-synucleins may act to suppress
a-synuclein aggregation and toxicity [20].
In immortalised cell lines and primary neuronal cultures,
both WT and PD mutant a-synuclein could be found
associated with the phospholipid surface layer of lipid
droplets [21] and are enriched in lipid rafts [22]. In the
rafts, a-synuclein was associated with speciﬁc PtdSer
species containing polyunsaturated fatty acids (PUFA) [23]
or with gangliosides [24, 25]. Moreover, polyunsaturated
fatty acyl groups were shown to promote multimerisation
of a-, b-, and c-synucleins [26] and lipid-associated olig-
omers of a-synuclein have been detected in the brain of
patients with a-synucleinopathies [27, 28]. It has been
suggested that a-synuclein—PUFA interactions can recip-
rocally regulate neuronal PUFA levels and the oligomeri-
sation stage of a-synuclein in normal and disease nervous
system [27, 28].
The importance of PUFA in brain structure and func-
tions is well established [29]. These fatty acids, especially
arachidonic acid (C20:4n-6, ARA) and docosahexaenoic
acid (C22:6n-3, DHA), are enriched in certain brain
phospholipids, for example, in PtdIns and PtdEtn, respec-
tively [30]. In animal models, an inadequate supply of n-3
fatty acids during prenatal and early postnatal development
decreases DHA levels in the brain. As a result, adult ani-
mals develop learning and memory deﬁcits, which can be
improved by dietary supplementation of DHA or other n-3
PUFA, e.g. a-linolenic acid (C18:3n-3, LnA) [31–33]. In
humans, mental development may be improved by dietary
DHA supplementation during infancy [34]. Conversely,
low levels of DHA in human brains are associated with the
risk of developing neurological diseases such as general-
ised peroxisomal disorders [35] and Alzheimer’s disease
(AD) [36, 37]. In contrast, elevated levels of DHA, doco-
satetraenoic acid and linoleic acid have been shown in
those brain areas of PD patients that contain a-synuclein
inclusions [28].
Although the precise mechanism of DHA-enriched
phospholipid action on cognitive function is still poorly
understood, possible effects on the blood–brain barrier,
membrane ﬂuidity, activity of certain enzymes, neural
signalling, ionic channels, and control of nerve growth
factor have all been suggested [38]. Recently, a neuro-
protective action of the n-3 PUFA, DHA and LnA, in PD
has been also demonstrated using rat and mice models of
this disease [39, 40]. Interestingly, expression of genes
encoding a-synuclein and c-synuclein increased in brains
of rats fed high n-3 PUFA diets [38]. In turn, an important
role of a-synuclein in brain lipid metabolism as well as for
fatty acid uptake and metabolism has been documented
[41–43].
In contrast to the well-studied role of a-synuclein in
lipid metabolism in the normal and diseased nervous sys-
tems, very little is known about the involvement of
c-synuclein in these processes. Nevertheless, some recent
studies demonstrated that c-synuclein is directly involved
in lipid metabolism in mature adipocytes ([44, 45] and our
unpublished observations). Therefore it was logical to
investigate a possible link between c-synuclein and lipids
in the nervous system.
Here we analysed lipid composition and fatty acid pat-
terns of individual lipids from brain regions of c-synuclein
null mutant (gammaKO) mice. We found that the level of
PtdSer is increased in the midbrain whereas no changes in
the relative proportions of membrane lipid classes were
observed in the cerebral cortex of these animals. In addi-
tion, higher percentages of DHA were found in both PtdSer
and PtdEtn from the cerebral cortex of gammaKO mice.
These data suggest a role for c-synuclein in lipid metabo-
lism in the nervous system and are discussed in relation to
what is known about alterations of lipid metabolism in
a-synuclein-deﬁcient animals.
Experimental Procedures
Materials
FA standards were obtained from Nu-Chek-Pre. Inc.
(Elysian, MN) and silica gel G plates were from Merck
KGaA (Darmstadt, Germany). Lipid standards were from
Sigma (Poole, UK). Other reagents were of the best
available grades and were from Fisher Scientiﬁc (Lough-
borough, UK).
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All animal work was carried in accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act (1986).
Production of c-synuclein null mutant mice on a pure
(C57Bl6J, Charles River) genetic background and the
method of animal genotyping by PCR have been described
previously [46, 47]. For this study, male c-synuclein null
mutant mice and their WT littermates were kept in indi-
vidual cages from the age of 9 weeks with access to water
and food ad libitum. Animals were fed special diet DOI
58Y2 with 10% energy from fats (LabDiets). No signiﬁcant
differences in animal weight and food uptake were
observed between groups of mutant and WT animals
throughout the experimental period. In order to evaluate
the effect of c-synuclein deﬁciency on the lipid composi-
tion in the fully-developed nervous system, tissues of
young but fully mature (21 week-old) adult mice were
analysed.
Lipid Analysis
At the age of 21 weeks animals were fasted for 4 h before
killing by lethal injection of phenobarbital. Lipids were
extracted immediately from dissected brain regions by a
modiﬁed Folch method [48]. In this procedure [originally
developed for mitochondrial lipids such as cardiolipin
(Ptd2Gro)] efﬁcient extraction even of highly polar com-
pounds is ensured.
Polar lipids were separated by two-dimensional TLC on
10 9 10 cm 1.2% boric acid-impregnated silica gel G
plates using chloroform: methanol: ammonium hydroxide
(65:25:4; v/v/v) in the ﬁrst dimension and then n-butanol:
acetic acid: water (90:20: 20; v/v/v) in the second. Plates
were sprayed with 0.05% (wt/vol) 8-anilino-4-naphthosul-
phonic acid in methanol and viewed under UV light to
reveal lipids. Preliminary identiﬁcation was made by ref-
erence to authentic standards and conﬁrmed using speciﬁc
colour reagents [49]. Additionally, the structural identiﬁ-
cation of lipids was conﬁrmed by mass spectrometry (see
next paragraph for details). Non-polar lipids were separated
using 1-dimensional TLC on 10 9 10 cm silica gel G
plates with double development using toluene: hexane:
formic acid (140:60:1, v/v/v) for the entire plate followed
by hexane: diethyl ether: formic acid (60:40:1, v/v/v) to
half height. Individual lipids were scraped from the TLC
plates and their fatty acid compositions and contents were
determined by gas chromatography using an internal
standard of pentadecanoate (for details, see ‘‘Fatty Acid
Analysis’’ section below) [49].
Mass spectrometry was performed on an Applied Bio-
systems 4000 Q-Trap. Lipid extracts were diluted in
methanol and introduced at 10 ll/min into the electrospray
source operating in the negative ion mode. All scans were
obtained using an ionspray voltage of -4,500 V and a
declustering potential of -140 V. Q1 scans were per-
formed scanning a mass range of 600–1,000 amu over 4 s,
with 10 scans acquired and averaged. MS/MS scans using
the ion trap mode of the Q-Trap were run at a scan rate of
1,000 amu/s with collision energies of -50 and -60 V,
and a linear ion trap (LIT) ﬁll time of 150 ms with Q0
trapping enabled. Again 10 scans were acquired and
averaged and the data analysed using the software Analyst
1.4.1.
Fatty Acid Analysis
Fatty acid methyl esters (FAME) were prepared by trans-
methylation with 2.5% H2SO4 in dry methanol/toluene
(2:1, by vol.). FAME were separated using a Clarus 500
gas chromatograph (Perkin-Elmer, Norwalk, Connecticut)
ﬁtted with a 30 m 9 0.25 mm i.d. capillary column (Elite
225, Perkin Elmer). The oven temperature was pro-
grammed: 170 C for 3 min, heated to 220 Ca t4C/min,
held at 220 C for 15 min. FAME were identiﬁed routinely
by comparing retention times with fatty acid standards
(Nu-Chek Prep. Inc., Elysian, USA) but conﬁrmation of the
structure of the major fatty acids had also been made by
MS. Quantiﬁcation was made with an internal standard of
pentadecanoate.
Statistics
Statistical signiﬁcance between groups was assessed by
Student’s t test.
Results
Fatty Acid Composition of Diet
The fatty acid composition of the diet used is presented in
Table 1. It contained oleic acid as a major compound (35%
of total diet FA) followed by linoleic (25%), palmitic
(20%) and stearic (13%) acids. The relative amount of
a-linolenic (an essential n-3 fatty acid) was low and did not
exceed 2.5% of total FA. Thus, the ratio of n-6/n-3 fatty
acids was high giving a value of 13 whereas a balanced
human diet is believed to range from 1:1 to 1:4 [50]. Lipids
accounted for 10% of total energy in this diet.
Fatty Acid Composition of Plasma
Fatty acid composition of plasma from WT and c-synuclein
null mutant mice (gammaKO) is present in Table 1. Pal-
mitic, stearic, oleic, linoleic and arachidonic acids were the
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amount of DHA in both, WT and gammaKO mice. The
relative amount of oleic acid was increased signiﬁcantly in
the plasma of gammaKO mice compared to WT (Table 1).
Cortex and Midbrain Fatty Acid Composition
of the Total Polar Lipids in WT and c-Synuclein Null
Mutant Mice
Table 2 shows the FA proﬁle of the total polar lipid frac-
tions from cortex or midbrain in WT and gammaKO mice.
Palmitic and stearic acids were dominant FA in cortex
followed by DHA, oleic acid and ARA. In midbrain, stearic
and oleic acids were the major compounds followed by
palmitic, DHA and ARA. The percentages of palmitic,
arachidonic and DHA in total polar lipids were signiﬁ-
cantly higher in the cortex region compared to midbrain in
both WT and gammaKO mice, whereas proportions of
oleic and nervonic (C24:1) acids were higher in this lipid
fraction from midbrain. There were no statistically signif-
icant differences in the relative proportions of fatty acids
from the total polar lipid fraction between WT and gam-
maKO mice in either brain region.
Polar Lipid Composition of Cortex and Midbrain
Regions from WT and gammaKO Mice
The relative proportions of different polar lipids in the two
brain regions are shown in Fig. 1. Three phospholip-
ids, namely phosphatidylcholine (PtdCho), ethanolamine
phospholipids and PtdSer, were the major polar lipids in
both brain regions (accounting for about 70–80% of the
total polar lipids). Phosphatidylinositol (PtdIns), sphingo-
myelin (CerPCho), Ptd2Gro as well as sulfatide and cere-
broside were present in smaller proportions and were each
less than 5% of the total polar lipids. Sulfatides and cere-
brosides were identiﬁed by electrospray ionisation tandem
mass spectrometry (ESI–MS-MS) [51, 52]. The relative
amounts of polar lipids did not vary much between mid-
brain and cortex samples from WT animals, although the
levels of sulfatides and PtdCho were higher and lower,
respectively, in the midbrain region (Fig. 1). In this brain
region, c-synuclein deﬁciency resulted in a statistically
signiﬁcant (*40%) increase in the relative proportion of
PtdSer compared to WT animals, whereas the proportions
of other lipids were not altered signiﬁcantly (Fig. 1). No
differences in the polar lipid composition were found in the
cortex of WT compared to gammaKO mice (Fig. 1). Also,
no differences in the concentrations of total polar lipids and
triacylglycerols (TAG) were observed for these brain
regions as a result of c-synuclein deﬁciency (data not
shown).
Table 1 Fatty acid composition (% total acids) of the diet and the
plasma from wild-type (WT) and c-synuclein null mutant (gam-
maKO) mice
Fatty acid Diet Plasma
WT gammaKO
C14:0 0.5 ± 0.1 tr. tr.
C16:0 20.3 ± 2.6 17.8 ± 4.7 19.8 ± 2.6
C16:1 (n-7) 1.0 ± 0.2 2.0 ± 0.7 3.1 ± 0.8
C18:0 12.6 ± 2.1 13.0 ± 2.2 13.0 ± 4.8
C18:1 (n-9) 35.0 ± 1.3 16.0 ± 1.9 20.5 ± 2.8*
C18:1 (n-7) 2.0 ± 0.1 2.2 ± 0.2 3.0 ± 0.8
C18:2 (n-6) 24.9 ± 6.0 17.3 ± 1.8 15.1 ± 1.8
C18:3 (n-3) 2.2 ± 0.6 0.5 ± 0.2 0.5 ± 0.3
C20:1 (n-9) 0.6 ± 0.2 tr. tr.
C20:3 (n-6) n.d. 1.6 ± 0.8 2.0 ± 0.7
C20:4 (n-6) n.d. 20.3 ± 4.5 15.9 ± 4.4
C22:6 (n-3) n.d. 7.3 ± 2.4 5.2 ± 1.9
Data as means ± SD (n = 3 for diet and n = 5 for plasma)
Fatty acids are indicated with the number before colon showing the
number of carbon atoms, the ﬁgure afterwards denoting the number of
double bonds. The position of the ﬁrst double bond is shown in
brackets. Only the major fatty acids (C0.5%) are listed
n.d. none detected; tr trace\0.5%
The asterisk (*) indicates a signiﬁcant effect of c-synuclein deﬁciency
when compared with WT (p\0.05)
Table 2 Fatty acid composition (% of total fatty acids) of the total
polar lipid fraction from cortex or midbrain of wild-type (WT) and
c-synuclein null mutant (gammaKO) mice
FA CORTEX MIDBRAIN
WT gammaKO WT gammaKO
C16:0 22.2 ± 0.5 22.6 ± 0.8 16.8 ± 0.2
# 17.5 ± 0.8
C16:1 (n-7) 1.3 ± 0.2 1.4 ± 0.2 0.1 ± 0.0
# 0.2 ± 0.0
C18:0 22.6 ± 0.4 22.8 ± 0.4 21.8 ± 2.3 21.6 ± 2.4
C18:1 (n-9) 15.9 ± 0.2 15.6 ± 0.3 21.7 ± 0.6
# 21.1 ± 1.1
C18:1 (n-7) 3.8 ± 0.4 4.0 ± 0.3 4.7 ± 1.3 5.0 ± 0.5
C18:2 (n-6) 0.9 ± 0.1 0.8 ± 0.1 2.8 ± 0.9
# 2.8 ± 0.8
C18:3 (n-3) 10.4 ± 0.5 10.5 ± 0.3 7.7 ± 0.9
# 7.4 ± 1.2
C20:3 (n-6) 2.4 ± 0.1 2.4 ± 0.1 3.0 ± 0.9 3.7 ± 2.0
C20:4 (n-6) 16.5 ± 2.0 16.0 ± 0.6 12.1 ± 1.7
# 11.5 ± 1.0
C22:6 (n-3) 0.8 ± 0.2 0.8 ± 0.2 2.5 ± 0.6
# 2.6 ± 0.6
Data as means ± SD (n = 6–8)
See legend to Table 1 for other details
The hash (#) indicates signiﬁcant differences between midbrain and
cortex in WT animals (p\0.05)
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Composition of Individual Polar Lipid Classes
in Cortex and Midbrain
Figures 2, 3 and Table 3 show data on the fatty acid
composition for the major polar lipids in cortex and mid-
brain from WT and gammaKO mice. These data show a
fatty acid distribution typical of that for murine brain
tissues.
PtdCho in both cortex and midbrain is characterised by a
domination of palmitate (about 48 and 40% in cortex and
midbrain, respectively), stearate (14 and 16%) and oleate
(21 and 24%) with much lower levels of the two major
brain long-chain polyunsaturated fatty acids, ARA and
DHA (Table 3). In the cortex, the relative concentrations of
ARA and DHA in PtdCho were about 6 and 3%, respec-
tively. In the midbrain, about 4% of each of ARA and DHA
was found in PtdCho. The levels of all above mentioned
fatty acids were signiﬁcantly different between the two
brain regions. In contrast, there were no signiﬁcant dif-
ferences in these parameters between WT and gammaKO
mice.
PtdIns is enriched with two fatty acids, stearic (around
44% in both cortex and midbrain) and ARA (37 and 34% in
cortex and midbrain, respectively). DHA is a minor com-
ponent in PtdIns and its relative concentration was about
2% in cortex and 4% in midbrain, these being signiﬁcantly
different. c-Synuclein deﬁciency resulted in an increased
level of ARA in PtdIns in cortex but did not affect the fatty
acid proﬁles of this lipid in midbrain (Table 3).
Oleic and ARA were the major acids found in brain
Ptd2Gro. In this lipid, another C18:1 isomer, cis-vaccenic
acid, was also present in appreciable amounts especially in
the midbrain (around 11 vs. 7% in cortex). The relative
concentration of ARA was higher in Ptd2Gro from the
cortex than in Ptd2Gro from the midbrain (18 and 13%,
Midbrain
Cortex
#
*
#
Fig. 1 Midbrain and cortex polar lipid composition (% of total polar
lipids) from wild-type (WT) and c-synuclein null mutant (gammaKO)
mice. Values represent mean ± SD, n = 5. The asterisk (*) indicates
a signiﬁcant effect of c-synuclein deﬁciency when compared with
WT, and the hash (#) indicates signiﬁcant differences between
midbrain (top panel) and cortex (bottom panel) in WT animals
(p\0.05 for both). CerPCho sphingomyelin, PtdCho phosphatidyl-
choline, PtdEtn phosphatidylethanolamine, Ptd2Gro cardiolipin,
PtdIns phosphatidylinositol, PtdSer phosphatidylserine, ST sulfatide,
Cer cerebroside
Midbrain
Cortex
#
#
*
*
*
#
*
Fig. 2 Fatty acid composition of phosphatidylserine from midbrain
or cortex in wild-type (WT) and c-synuclein null mutant (gammaKO)
mice. Values represent mean ± SD, n = 5. The asterisk (*) indicates
a signiﬁcant effect of c-synuclein deﬁciency when compared with
WT, and the hash (#) indicates signiﬁcant differences between
midbrain (top panel) and cortex (bottom panel) in WT animals
(p\0.05 for both). See legend to Table 1 for identiﬁcation of fatty
acids
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from the brain, Ptd2Gro contains higher levels of C16
and C18 monoenic acids, namely C16:1n-7 (up to 5%),
C18:1n-9 (up to 38%) and C18:1n-7 (up to 15%). The
proportion of the latter was signiﬁcantly higher in the
midbrain than in cortex at the expense of arachidonic acid
(Table 3). No statistically signiﬁcant changes were found
when comparing Ptd2Gro fatty acid proﬁles in the cortex
between WT and gammaKO animals, whereas in midbrain
the proportion of C18:1n-7 was increased in gammaKO
mice compared to WT (Table 3).
CerPCho from both cortex and midbrain contains stearic
acid as its main fatty acid (up to 81% of total FAs in cortex,
and up to 65% of that in midbrain). The presence of two
very long chain acids, lignoceric (C24:0) and nervonic
(C24:1n-6), is also characteristic for this lipid. Their levels
were higher in midbrain than cortex. CerPCho fatty acids
were unchanged as a response to c-synuclein deﬁciency in
Midbrain 
Cortex
#
*
* #
#
# #
Fig. 3 Fatty acid and dimethylacetal composition of ethanolamine
phospholipids from midbrain or cortex in wild-type (WT) and
c-synuclein null mutant (gammaKO) mice. Values represent
mean ± SD, n = 5. The asterisk (*) indicates a signiﬁcant effect of
c-synuclein deﬁciency when compared with WT, and the hash (#)
indicates signiﬁcant differences between midbrain (top panel) and
cortex (bottom panel) in WT animals (p\0.05 for both)
Table 3 Fatty acid composition (% of total fatty acids) in individual
polar lipid classes from cortex or midbrain of wild-type (WT) and
c-synuclein null mutant (gammaKO) mice
FA CORTEX MIDBRAIN
WT gammaKO WT gammaKO
Phosphatidylcholine
C16:0 48.0 ± 2.7 45.2 ± 1.9 39.2 ± 3.5
# 39.2 ± 2.6
C16:1 (n-7) 0.7 ± 0.1 0.8 ± 0.3 0.7 ± 0.2 0.9 ± 0.2
C18:0 3.7 ± 0.7 13.0 ± 0.7 16.5 ± 1.2
# 15.1 ± 1.6
C18:1 (n-9) 20.6 ± 0.8 20.9 ± 1.1 24.1 ± 1.6
# 23.9 ± 1.1
C18:1 (n-7) 5.1 ± 2.0 6.8 ± 0.9 7.2 ± 0.6 8.1 ± 1.6
C20:1 (n-9) 0.7 ± 0.1 0.7 ± 0.1 1.7 ± 0.5
# 1.6 ± 0.3
C20:4 (n-6) 5.7 ± 0.6 6.4 ± 0.5 3.9 ± 0.7
# 4.1 ± 0.6
C22:6 (n-3) 3.2 ± 0.5 3.8 ± 0.4 3.7 ± 0.6 4.3 ± 0.6
Phosphatidylinositol
C16:0 8.2 ± 1.8 6.7 ± 1.9 7.3 ± 1.8 9.4 ± 2.1
C18:0 44.1 ± 3.2 40.7 ± 1.1 44.9 ± 3.2 40.7 ± 2.1
C18:1 (n-9) 5.1 ± 0.8 5.1 ± 0.6 5.5 ± 0.5 8.4 ± 2.4*
C18:1 (n-7) 2.2 ± 0.2 2.5 ± 0.4 2.5 ± 0.4 3.4 ± 0.7
C20:4 (n-6) 36.8 ± 3.5 41.8 ± 2.4* 33.5 ± 3.6 32.4 ± 1.1
C22:6 (n-3) 2.0 ± 0.8 2.2 ± 0.5 4.6 ± 1.7
# 4.2 ± 1.3
Cardiolipin
C16:0 6.7 ± 2.2 6.1 ± 2.2 7.8 ± 1.3 8.5 ± 1.9
C16:1 (n-7) 5.3 ± 1.1 5.1 ± 1.1 4.1 ± 2.6 4.8 ± 1.6
C18:0 8.1 ± 3.4 8.2 ± 3.5 10.6 ± 3.3 6.8 ± 2.9
C18:1 (n-9) 38.1 ± 2.2 36.4 ± 2.2 36.8 ± 2.3 33.9 ± 3.2
C18:1 (n-7) 6.9 ± 0.7 5.8 ± 0.9 10.5 ± 2.3
# 15.4 ± 3.0*
C18:2 (n-6) 5.7 ± 2.1 4.8 ± 0.4 3.9 ± 0.6 4.2 ± 0.5
C20:3 (n-6) 1.9 ± 0.2 2.3 ± 0.4 1.7 ± 0.2 1.8 ± 0.2
C20:4 (n-6) 17.7 ± 2.3 19.4 ± 2.1 13.1 ± 2.2
# 13.4 ± 0.8
C22:6 (n-3) 9.4 ± 2.3 11.5 ± 3.3 10.4 ± 2.9 10.7 ± 1.4
Sphingomyelin
C16:0 4.8 ± 2.1 5.2 ± 2.0 5.2 ± 2.3 6.9 ± 4.0
C16:1 (n-7) 0.8 ± 0.2 0.7 ± 0.4 1.2 ± 0.6 1.6 ± 0.6
C18:0 80.6 ± 3.4 77.8 ± 1.7 65.0 ± 8.4
# 55.1 ± 5.8*
C18:1 (n-9) 0.5 ± 0.2 1.2 ± 0.5 0.7 ± 0.3 1.7 ± 0.8
C20:0 2.3 ± 0.3 2.3 ± 0.3 2.8 ± 0.4 2.4 ± 0.2
C22:0 2.7 ± 0.5 2.4 ± 0.5 5.0 ± 2.1 4.6 ± 1.6
C24:0 2.1 ± 0.4 1.7 ± 0.4 4.5 ± 2.5 3.9 ± 1.0
C24:1 (n-6) 4.1 ± 2.1 7.3 ± 1.9 11.1 ± 5.7 19.9 ± 9.3
Sulfatide
C16:0 6.9 ± 3.1 8.6 ± 1.8 7.9 ± 2.4 8.4 ± 2.4
C16:1 (n-7) 1.7 ± 0.2 1.8 ± 0.5 1.7 ± 1.0 1.6 ± 0.9
C18:0 20.7 ± 2.9 23.6 ± 2.4 19.0 ± 2.8 16.5 ± 3.5
C18:1 (n-9) 11.5 ± 1.7 13.2 ± 3.6 13.3 ± 1.4 14.1 ± 2.8
C18:1 (n-7) 1.4 ± 0.4 1.7 ± 0.4 2.2 ± 0.7 1.5 ± 0.9
C20:0 1.6 ± 0.2 1.5 ± 0.3 1.5 ± 0.4 1.3 ± 0.2
C20:1 (n-9) 1.6 ± 0.5 1.5 ± 0.7 2.2 ± 0.7 1.9 ± 0.6
C20:4 (n-6) 2.1 ± 1.1 2.3 ± 1.3 2.0 ± 0.5 2.2 ± 0.6
C22:0 6.6 ± 1.1 5.8 ± 0.8 6.0 ± 0.8 5.4 ± 0.8
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123the cortex whereas in the midbrain decreased percentages
of C18:0 was found.
Fatty acids from both sulfatides and cerebrosides did
not show any differences between cortex and midbrain.
c-Synuclein deﬁciency resulted in a decreased proportion
of lignoceric acid in sulfatides and cerebrosides in the
cortex (Table 3). In midbrain region, a reduced relative
proportion of behenic acid (C22:0) was found in cerebro-
sides in gammaKO mice (Table 3).
The fatty acid composition of PtdSer and PtdEtn which,
in brain tissues, represent two lipid classes signiﬁcantly
enriched with the n-3 PUFA, DHA, are shown in Figs. 2
and 3, respectively. For PtdSer, the levels of both C18:0
and DHA were higher in cortex compared to midbrain
while oleate was reduced (Fig. 2). Moreover, the level of
DHA in PtdSer was signiﬁcantly increased in the cortex of
gammaKO mice compared to WT animals (30.0 and 25.8%
of total FA, respectively) with a concomitant decrease in
the proportion of stearate (C18:0) (Fig. 2). PtdEtn con-
tained both ARA and DHA as major fatty acids and, similar
to PtdSer, the proportion of DHA was enhanced signiﬁ-
cantly in cortex tissue (25.4%) in gammaKO mice as
compared to control (21.4%). The proportions of ARA
were unaffected by c-synuclein deﬁciency in PtdEtn from
both cortex and midbrain tissues (Fig. 3). In addition to
fatty acids from the diacyl form of PtdEtn, we also
analysed the proﬁle of dimethylacetal (DMA) derivatives
that represent aliphatic chains from ether derivatives
(mainly plasmalogens) of PtdEtn (Fig. 3). Four DMA were
identiﬁed with a domination of C18:0-DMA, but no sig-
niﬁcant changes in the relative proportion of these com-
pounds in cortex and midbrain were found between WT
and gammaKO mice.
In addition to the polar lipid classes described above, a
C2-ceramide, N-acetylsphingosine, was present in lipid
extracts from both cortex and midbrain in small but sig-
niﬁcant amounts [53]. The structure of this ceramide was
elucidated by using ESI–MS (data not shown).
Discussion
The importance of lipids in neural tissue physiology and
cell signalling has been demonstrated by the association of
lipid imbalances and/or deregulated lipid metabolism with
the development of various CNS disorders, including
Alzheimer’s disease, Parkinson’s disease, Niemann–Pick
disease, multiple sclerosis, Huntington’s disease, amyo-
trophic lateral sclerosis, schizophrenia, bipolar disorders
and epilepsy [54]. Recently, relationships between glu-
cosylsphingosine accumulation due to mutations in the
glucocerebrosidase gene (GBA) and Parkinsonism as well
as dementia with Lewy bodies, have been reported [55, 56].
Because alterations in brain lipid biochemistry have been
previously linked to the a-synuclein deﬁciency [41, 57] and
since c-synuclein and a-synuclein are closely-related pro-
teins, whose functions are potentially redundant [47, 58,
59], it was clearly important to evaluate if c-synuclein
might also be involved in brain lipid homeostasis. In our
study we examined the lipid composition of two brain
regions, the midbrain that exhibits relatively high level of
c-synuclein expression, and the cerebral cortex, where
expression level of this protein is substantially lower
[46, 60].
No effect of c-synuclein deﬁciency on the total polar
lipid content and TAG accumulation in the cerebral cortex
and midbrain was revealed in our work (data not shown).
This contrasts to studies with a-synuclein deﬁcient mice
where an increase in TAG content of the whole brain has
been demonstrated [41].
The mitochondria-speciﬁc phospholipid, Ptd2Gro, which
was found in both regions studied (4% of the total polar
lipids), was not affected by c-synuclein deﬁciency (Fig. 1).
The fatty acid proﬁle of Ptd2Gro was also almost the same
(Table 3). This was different from a-synuclein deﬁcient
mice that had a reduced total brain Ptd2Gro content with a
strongly altered acyl chain composition, a mitochondrial
lipid abnormality possibly associated with electron trans-
port chain impairment in the brain of PD patients [42].
Table 3 continued
FA CORTEX MIDBRAIN
WT gammaKO WT gammaKO
C24:0 14.4 ± 2.0 11.5 ± 2.1* 12.9 ± 2.6 11.7 ± 1.2
C24:1 (n-6) 28.8 ± 4.9 27.7 ± 4.3 29.2 ± 3.7 34.5 ± 5.2
Cerebroside
C16:0 3.1 ± 0.7 5.3 ± 2.7 3.7 ± 1.3 5.0 ± 2.5
C16:1 (n-7) 1.7 ± 0.2 1.7 ± 0.8 1.4 ± 0.7 0.8 ± 0.1
C18:0 11.4 ± 4.2 13.2 ± 4.4 12.1 ± 2.9 9.1 ± 3.0
C18:1 (n-9) 2.8 ± 1.1 4.6 ± 2.8 4.0 ± 0.7 7.0 ± 3.1
C18:1 (n-7) 0.4 ± 0.1 0.4 ± 0.2 0.8 ± 0.5 1.2 ± 0.5
C20:0 2.5 ± 0.1 2.0 ± 0.4 1.8 ± 0.5 1.6 ± 0.7
C20:1 (n-9) 0.4 ± 0.2 0.6 ± 0.3 0.8 ± 0.3 1.4 ± 0.5
C20:4 (n-6) 1.5 ± 0.9 2.3 ± 1.0 1.7 ± 1.0 2.2 ± 0.4
C22:0 12.0 ± 1.6 9.1 ± 1.7 10.2 ± 1.6 7.5 ± 0.8*
C22:1 1.9 ± 0.8 2.5 ± 0.2 2.0 ± 0.2 2.3 ± 0.3
C24:0 22.8 ± 4.0 15.7 ± 3.7* 21.4 ± 4.3 15.2 ± 2.8
C24:1 (n-6) 39.6 ± 6.5 42.4 ± 5.5 40.2 ± 6.3 46.9 ± 4.7
Data as means ± SD (n = 6–7)
See legend to Table 1 for other details
The asterisk (*) indicates a signiﬁcant effect of c-synuclein deﬁciency
when compared with WT (p\0.05). The hash (#) indicates signiﬁ-
cant differences between midbrain and cortex in WT animals
(p\0.05)
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affects mitochondrial function in the nervous system.
Similar to a-synuclein deﬁciency [41], c-synuclein
deﬁciency did not change the level of ethanolamine phos-
pholipids (Fig. 1). The plasmenyl species of PtdEtn are
important phospholipid components of most electroactive
cellular membranes, such as cardiac sarcolemma and
neuronal cell membranes. Between one-half and two-thirds
of the ethanolamine phospholipids in the whole brain are in
plasmalogen form, and 11–12% of myelin phospholipids
are plasmalogens [61]. A deﬁciency of ethanolamine
plasmalogens has been shown to be associated with aging
and some degenerative diseases, especially those associ-
ated with peroxisomal disorders [62–64]. The absence of
ethanolamine plasmalogen alterations is consistent with
only mild alterations in normal neural function in both
a-synuclein and c-synuclein deﬁcient mice. However, fur-
ther comparative studies of aging mice would be important,
due to various effects of aging on their nervous systems
[65].
Among polar lipids, only the relative proportion of
PtdSer changed in gammaKO in comparison to WT mice
(Fig. 1). This change was evident only in the midbrain
region where expression of c-synuclein is much higher than
in the cerebral cortex [46]. Although this increase was
relatively minor in the whole midbrain tissue, the changes
in PtdSer content may be much more pronounced in spe-
ciﬁc neuronal populations since c-synuclein has been
shown to be expressed only in a subset of midbrain neurons
[46]. Previously, increases in PtdSer have been noted in
plasma membrane phospholipids from affected regions of
AD brains [63] where they may induce formation of
amyloid ﬁbers [66]. It is also of note, that PtdSer has roles
in apoptosis, in the regulation of many enzymes and in
control of the channel function of the acetylcholine
receptor [62, 67, 68]. Thus, alteration in PtdSer may have
implications for neuronal cell functions. However, the
changes observed were not sufﬁcient for triggering patho-
logical alterations in the nervous system of c-synuclein
deﬁcient mice [46, 47, 59].
Three lipid classes in brain contain high levels of PUFA.
Whereas PtdSer and PtdEtn are enriched in DHA, PtdIns
contains substantial amounts of ARA. When comparing
midbrain and cortex regions, the latter was enriched in
ARA but depleted in DHA (Table 2). These differences
may be partly explained by higher content of PtdCho
(Fig. 1), which possesses elevated levels of ARA, in the
cerebral cortex (Table 3). Interestingly, statistically sig-
niﬁcant changes were found in the relative amount of
PtdSer in the midbrain region of c-synuclein null mutant
mice (Fig. 1) and in the DHA content of both PtdSer
(Fig. 2) and ethanolamine phospholipids (Fig. 3) in the
cerebral cortex. Because only a limited number of cortical
neurons normally express c-synuclein, changes of DHA
levels in these cells might be much more profound than
those revealed by analysis of total cortex phospholipids. It
is noteworthy that although a-synuclein null mutant mice
had slightly decreased levels of DHA in the whole brain
PtdEtn and PtdSer, an increased uptake of this fatty acid
into brain phospholipids has also been reported [69]. It is
well known that DHA is essential to perinatal neurological
development during which it increases in the CNS. The
high demand for DHA in the brain is maintained either by
dietary supply or by biosynthesis from a-linolenate within
the liver [33]. Since no very long-chain PUFA were present
in the diet, and no changes in the liver (data not shown) or
plasma PUFA proﬁles (Table 1) were found, we suggest
that the differences in DHA levels are most likely related to
possible effects of c-synuclein deﬁciency on DHA metab-
olism in the developing brain. Alternatively, complete
absence of c-synuclein might trigger systemic changes,
including alterations in adipose and other tissues normally
expressing this protein, that activate compensatory mech-
anisms during brain development.
There is a growing body of evidence about the impor-
tance of PUFA in brain function where its deﬁciency is
associated with cognitive decline during aging and with
neurodegenerative diseases [70]. The beneﬁcial neuro-
physiological role of DHA most probably relates to
metabolites such as eicosanoids and other autacoids which
are important as modulators of membrane microdomain
composition, receptor signalling and gene expression [71].
Recent studies demonstrated a role for neuroprotectin D1
(NPD1) in the homeostatic regulation of brain cell survival
and repair involving neurotrophic, anti-apoptotic and anti-
inﬂammatory signalling in AD [70]. Unfortunately, there is
no information about the possible involvement of such
DHA metabolites in PD. But the gammaKO mutants,
which exhibit higher levels of DHA accumulation in cer-
tain brain regions, may be a useful model for future
research in this area.
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